Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PCSK9: an emerging player in cardiometabolic aging and its potential as a therapeutic target and biomarker

18 Dec 2023

Abstract excerpt

Proprotein convertase subtilisin/kexin type 9 (PCSK9), renowned for its pivotal role in low-density lipoprotein (LDL) regulation, has emerged as a compelling regulator of cardiometabolic aging. Beyond its well-established involvement in cholesterol metabolism, PCSK9's multifaceted influence on the aging processes of the cardiovascular and metabolic systems is garnering increasing attention. This review delves...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Computational Drug Discovery Methods
Share to Hormonal Regulation and Hypertension
Share to Lipoproteins and Cardiovascular Health

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38105401
DOI: 10.1007/s11357-023-01003-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PCSK9: an emerging player in cardiometabolic aging and its potential as a therapeutic target and biomarkerPMID 38105401Read ↗

PCSK9: a key modulator of cardiovascular health.Semantic proximity Read ↗

Physiology and role of PCSK9 in vascular disease: Potential impact of localized PCSK9 in vascular wall.Semantic proximity Read ↗

Molecular biology of PCSK9: its role in LDL metabolism.Semantic proximity Read ↗

Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.Semantic proximity Read ↗

The PCSK9 decade.Semantic proximity Read ↗

Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition.Semantic proximity Read ↗

The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.Semantic proximity Read ↗

PCSK9 and Lipid Metabolism: Genetic Variants, Current Therapies, and Cardiovascular Outcomes.Semantic proximity Read ↗

Clinical aspects of PCSK9.Semantic proximity Read ↗

Genomic and Precision Medicine Approaches in Atherosclerotic Cardiovascular Disease: From Risk Prediction to Therapy—A ReviewSemantic proximity Read ↗

Cardiovascular Pathologies: A Comprehensive Review of Mechanisms, Risk Factors, and Advanced Therapeutic ModalitiesSemantic proximity Read ↗

Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.